| 8147- | Lae, | Mechanisms underlying the therapeutic effects of Amygdalin in treating Cervical Cancer based on multi-omics analysis |
| - | in-vitro, | Cerv, | Ca9-22 | - | in-vitro, | Cerv, | HeLa |
| 866- | Lae, | Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review |
| - | Review, | NA, | NA |
| 870- | Lae, | Physician Beware: Severe Cyanide Toxicity from Amygdalin Tablets Ingestion |
| - | Case Report, | NA, | NA |
| 869- | Lae, | Recent updates and future perspectives about amygdalin as a potential anticancer agent: A review |
| 868- | Lae, | The Postulated Mechanism of Action of Amygdalin (Vitamin B17) on Cancer Cells |
| - | Review, | NA, | NA |
| 867- | Lae, | Effects of the Gut microbiota on Amygdalin and its use as an anti-cancer therapy: Substantial review on the key components involved in altering dose efficacy and toxicity |
| - | Review, | NA, | NA |
| 859- | Lae, | Vitamin B17 and its Proposed Application in Treating Cancer |
| - | Analysis, | NA, | NA |
| 860- | Lae, | Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery |
| - | Review, | NA, | NA |
| 861- | Lae, | Chit, | AgNPs, | Synthesis of polygonal chitosan microcapsules for the delivery of amygdalin loaded silver nanoparticles in breast cancer therapy |
| 862- | Lae, | Molecular mechanism of amygdalin action in vitro: review of the latest research |
| - | Review, | NA, | NA |
| 863- | Lae, | Amygdalin inhibits the growth of renal cell carcinoma cells in vitro |
| - | in-vitro, | RCC, | NA |
| 864- | Lae, | Can Amygdalin Provide any Benefit in Integrative Anticancer Treatment? |
| - | Review, | NA, | NA |
| 865- | Lae, | Amygdalin: A Review on Its Characteristics, Antioxidant Potential, Gastrointestinal Microbiota Intervention, Anticancer Therapeutic and Mechanisms, Toxicity, and Encapsulation |
| 2351- | lamb, | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 8155- | lamb, | Ethanol extract of Pinus koraiensis leaves containing lambertianic acid exerts anti-obesity and hypolipidemic effects by activating adenosine monophosphate-activated protein kinase (AMPK) |
| - | vitro+vivo, | Nor, | 3T3 |
| 8154- | lamb, | Anti-allergic effect of lambertianic acid from Thuja orientalis in mouse bone marrow-derived mast cells |
| - | in-vitro, | Nor, | NA |
| 8152- | lamb, | TRAIL/rTRAIL, | Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4 |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 8158- | lamb, | Effect of Pinus koraiensis leaf extract on fatigue reduction and exercise performance: study protocol for a randomized, double-blind, placebo-controlled clinical trial |
| - | Trial, | Nor, | NA |
| 8151- | lamb, | Suppression of STAT3 Phosphorylation and RelA/p65 Acetylation Mediated by MicroRNA134 Plays a Pivotal Role in the Apoptotic Effect of Lambertianic Acid |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8149- | lamb, | Apoptotic effect of lambertianic acid through AMPK/FOXM1 signaling in MDA-MB231 breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8148- | lamb, | Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells |
| - | in-vitro, | Pca, | LNCaP |
| 8156- | lamb, | A review on chemistry, source and therapeutic potential of lambertianic acid |
| - | Review, | Var, | NA |
| 8157- | lamb, | Pinus koraiensis leaf extract and lambertianic acid attenuate fatigue and improve endurance capacity via PI3K-mediated regulation of oxidative stress and mitochondrial biogenesis |
| - | in-vivo, | Nor, | NA |
| 8174- | Lap, | Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases |
| - | in-vitro, | Var, | NA |
| 8173- | Lap, | Tras, | Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials |
| - | Review, | BC, | NA |
| 8172- | Lap, | Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study |
| - | Trial, | BC, | NA |
| 8171- | Lap, | Effects of food on the relative bioavailability of lapatinib in cancer patients |
| - | Trial, | Var, | NA |
| - | Trial, | BC, | NA |
| 8169- | Lap, | Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells |
| - | in-vitro, | Liver, | HepG2 |
| 8167- | LapC, | Characterization of lapachol cytotoxicity: contribution of glutathione depletion for oxidative stress in Saccharomyces cerevisiae |
| - | in-vitro, | Nor, | NA |
| 8160- | LapC, | Crystallographic Structure of Human Dihydroorotate Dehydrogenase in Complex with the Natural Product Inhibitor Lapachol |
| - | Study, | Var, | NA |
| 8161- | LapC, | Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 | - | in-vitro, | ESCC, | KYSE-510 |
| 8162- | LapC, | Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2 |
| - | in-vitro, | Melanoma, | MEL526 | - | in-vitro, | Melanoma, | MEL697 | - | in-vitro, | Melanoma, | MEL103 |
| 8163- | LapC, | Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis |
| - | in-vivo, | Arthritis, | NA |
| 8164- | LapC, | Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II |
| - | vitro+vivo, | GBM, | NA |
| 8165- | LapC, | Lapachol interferes with the cell cycle and inhibits proliferation and migration of bladder tumor cells with effects on ncRNA expression |
| - | in-vitro, | Bladder, | RT4 |
| 8166- | LapC, | Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model |
| - | vitro+vivo, | BC, | NA |
| 8168- | LapC, | VitK3, | Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol |
| - | in-vitro, | Melanoma, | B16-BL6 |
| 8175- | Las, | Lasiodin Inhibits Proliferation of Human Nasopharyngeal Carcinoma Cells by Simultaneous Modulation of the Apaf-1/Caspase, AKT/MAPK and COX-2/NF-κB Signaling Pathways |
| - | in-vitro, | NPC, | NA |
| 8176- | Las, | In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model |
| - | vitro+vivo, | BC, | NA |
| 8177- | Las, | Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8178- | Las, | Lasiokaurin suppresses breast cancer growth by blocking autophagic flux and regulating cellular energy homeostasis |
| - | in-vitro, | BC, | NA |
| 8179- | Las, | Lasiokaurin suppresses hepatocellular carcinoma proliferation and induces apoptosis via the JAK2/STAT3 pathway |
| - | in-vitro, | HCC, | NA |
| 8249- | LCA, | Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells |
| - | in-vitro, | NSCLC, | NA |
| 8237- | LCA, | Role of Licochalcone A in Potential Pharmacological Therapy: A Review |
| - | Review, | Var, | NA |
| 8248- | LCA, | Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H460 |
| 8247- | LCA, | Hepatic metabolism of licochalcone A, a potential chemopreventive chalcone from licorice (Glycyrrhiza inflata), determined using liquid chromatography-tandem mass spectrometry |
| - | Study, | Nor, | NA |
| 8246- | LCA, | Licochalcone A activates Keap1-Nrf2 signaling to suppress arthritis via phosphorylation of p62 at serine 349 |
| - | in-vivo, | Arthritis, | NA |
| 8245- | LCA, | Licochalcone A Upregulates Nrf2 Antioxidant Pathway and Thereby Alleviates Acetaminophen-Induced Hepatotoxicity |
| - | in-vivo, | LiverDam, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid